Zobrazeno 1 - 10
of 14
pro vyhledávání: '"James Foti"'
Autor:
Wendy Broom, Elizabeth M. Jaffee, Daniel DeOliveira, Victoria L. DeVault, Charles G. Drake, Ulka N. Vaishampayan, Arthur P. Decillis, Vijetha Vemulapalli, Maura L. Gillison, Mark N. Stein, Pamela M. Carroll, Kyle Ferber, Parul Agnihotri, Emily Tjon, Hubert Lam, Jessica Flechtner, James Foti, Roger B. Cohen, Lisa K. McNeil, Hanna Starobinets, Melissa Lynne Johnson, Przemyslaw Twardowski, Thomas A. Davis, Kwok-Kin Wong
Publikováno v:
Cancer Discovery. 11:696-713
Neoantigens are critical targets of antitumor T-cell responses. The ATLAS bioassay was developed to identify neoantigens empirically by expressing each unique patient-specific tumor mutation individually in Escherichia coli, pulsing autologous dendri
Autor:
Harshal Zope, Rounak Nande, Manish Jain, Charley Hubbard, Louisa Dowal, James Foti, James Loizeaux, Crystal Cabral, Daniel B. DeOliveira, Guohan Yang, Mercay Reuter, Jessica Baker Flechtner, Raymond Stapleton
Publikováno v:
Cancer Research. 82:2745-2745
Background: Neoantigen (neoAg)-specific T cells can be found in the peripheral blood of patients with solid tumors, and the infiltration of fresh, peripherally derived T cells into tumors has been associated with successful outcomes after checkpoint
Autor:
Maura Gillison, Jiaxin Niu, Daniel Olson, Mark Stein, David Aggen, Utkarsh Acharya, Benjamin Creelan, Richard Hernandez, Jessica Price, Kevin J. Mancini, Louisa Dowal, James Foti, Vijetha Vemulapalli, Mara Shainheit, Masoud Golshadi, Raymond D. Stapleton, Jessica B. Flechtner, Thomas A. Davis
Publikováno v:
Cancer Research. 82:CT153-CT153
TiTAN™ is an open-label, multi-center Phase1/2a trial evaluating safety, tolerability, T-cell persistence and proliferation, and clinical activity in patients with some solid tumors. Adoptive T-cell therapies (ACT) have resulted in durable clinical
Autor:
Melissa Hayes, James Loizeaux, James Perry, Jason R. Dobson, Wendy Broom, Mariya Croll, Anna Lyubetskaya, Crystal Cabral, Christopher L. Warren, James Foti, F. Stephen Hodi, Jessica Flechtner, Louisa Dowal
Publikováno v:
Cancer Research. 79:LB-223
Broadly reinvigorating the T cell response by blocking immune-inhibitory receptors can produce durable clinical benefit in 20-40% of melanoma patients. Due to low response rates and potential toxicity of checkpoint therapy, identification of biomarke
Publikováno v:
TrAC Trends in Analytical Chemistry. 49:89-99
Drug degradation prediction, chemical-based experiments, isolation and structure-elucidation techniques are all tools used to develop drug candidates. Structure elucidation often requires isolation, degradation chemistry, mass spectrometry and nuclea
Autor:
Michael O'Keefe, Abha Dhaneshwar, Catarina V. Nogueira, Wendy Broom, Jessica Flechtner, Pamela Carroll, Hanna Starobinets, Jason R. Dobson, James Foti, Erick Donis, Huilei Xu, Hubert Lam, Kyle Ferber, James Loizeaux, Paul Kirschmeier
Publikováno v:
Cancer Research. 78:5718-5718
Neoantigens are emerging as attractive vaccine targets for personalized cancer immunotherapy. As opposed to tumor-associated antigens, neoantigens contain non-synonymous mutations that enable their identification as foreign targets not subject to cen
Autor:
Michael O'Keeffe, Jason R. Dobson, Christopher L. Warren, James Foti, Ning Wu, Jin Yuan, Huilei Xu, Johanna K. Kaufmann, Jessica Flechtner, Pamela Carroll, Kyle Ferber, Crystal Cabral, Wendy Broom, Erick Donis, James Loizeaux
Publikováno v:
Cancer Research. 78:730-730
Neoantigens arise from tumor-specific, somatic mutations and have the potential to be recognized by T cells that are associated with anti-tumor immune responses. Since they are non-self, they are hypothesized to provide an attractive therapeutic moda
Autor:
Marcela Nefliu, Steven W. Baertschi, Paul A. Harmon, Todd Zelesky, Gregory W. Sluggett, Patrick J. Jansen, Christopher James Foti
Publikováno v:
Journal of pharmaceutical sciences. 104(12)
We report artifactual degradation of pharmaceutical compounds containing primary and secondary amines during peroxy radical-mediated oxidative stress carried out using azoalkane initiators. Two degradation products were detected when model drug compo
Autor:
Morris J. Dworkin, James R. Nechvatal, James Foti, Elaine B. Barker, Donna F. Dodson, E Roback
Publikováno v:
Journal of Research of the National Institute of Standards and Technology
In 1997, the National Institute of Standards and Technology (NIST) initiated a process to select a symmetric-key encryption algorithm to be used to protect sensitive (unclassified) Federal information in furtherance of NIST’s statutory responsibili